23. SYSTEMATIC REVIEW OF THE COST - EFFECTIVENESS OF PEMBROLIZUMAB IN RECURRENT OR METASTATIC CERVICAL CANCER. YHCĐ. 2025;66(CĐ8-NCKH). doi:10.52163/yhc.v66iCD8.2569